临床局限性前列腺癌中多参数磁共振可见与不可见病灶的基因组评估
研究对6例中高危前列腺癌根治术后的43个前列腺穿刺芯(22个肿瘤、21个良性)进行低深度全基因组、外显子、甲基化和转录组分析。mpMRI可见肿瘤内部存在基因组、表观基因组和转录组异质性,可能导致基于拷贝数或RNA表达的分类器误判;6个mpMRI不可见肿瘤芯中3个携带转移性去势抵抗性前列腺癌常见基因改变。作者认为不应仅凭mpMRI阴性省略系统穿刺。
要点
- mpMRI可见前列腺肿瘤内部存在基因组、表观基因组和转录组异质性。
- 单一穿刺芯基因组分析可能导致患者分类错误。
- 6个mpMRI不可见肿瘤芯中3个携带转移性去势抵抗性前列腺癌常见基因改变。
核心结论
- 研究支持在mpMRI基础上继续使用系统前列腺穿刺,因为对mpMRI阴性患者省略系统穿刺可能漏诊携带转移性前列腺癌常见基因改变的临床显著肿瘤。
- 应用基因组分类器时个体基因组学存在不一致性。
研究设计与样本
- 对中高危前列腺癌根治术后立即取新鲜前列腺组织进行多芯分析。
- 对同一前列腺显微镜下良性和癌区域的穿刺芯进行低深度全基因组、外显子、甲基化和转录组分析。
- 从5例患者血液中评估循环游离DNA和胚系DNA。
- 共分析6个完整前列腺的43个前列腺穿刺芯,其中22个肿瘤芯、21个良性芯。
主要发现
- 22个肿瘤芯中16个为mpMRI可见肿瘤,6个为mpMRI不可见肿瘤。
- mpMRI可见病灶内存在肿瘤内基因组、表观基因组和转录组异质性。
- 6个mpMRI不可见肿瘤芯中3个携带一种或多种转移性去势抵抗性前列腺癌常见基因改变。
- 未发现循环游离DNA改变。
临床怎么用
- 作者认为,对mpMRI阴性患者省略系统穿刺可能漏诊携带转移性前列腺癌常见基因改变的临床显著肿瘤。
- 作者认为,仅用单一穿刺芯进行基因组分析时,mpMRI可见肿瘤内的异质性可能导致患者分类错误。
局限性
- 局限性包括队列规模小和缺乏随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prostate cancer (PCa) diagnostic pathway is undergoing a radical change with the introduction of multiparametric magnetic resonance imaging (mpMRI), genomic testing, and different prostate biopsy techniques. It has been proposed that these tests should be used in a sequential manner to optimise risk stratification. OBJECTIVE: To characterise the genomic, epigenomic, and transcriptomic features of mpMRI-visible and -nonvisible PCa in clinically localised disease. DESIGN, SETTING, AND PARTICIPANTS: Multicore analysis of fresh prostate tissue sampled immediately after radical prostatectomy was performed for intermediate- to high-risk PCa. INTERVENTION: Low-pass whole-genome, exome, methylation, and transcriptome profiling of patient tissue cores taken from microscopically benign and cancerous areas in the same prostate. Circulating free and germline DNA was assessed from the blood of five patients. OUTCOME MEASUREMENT AND STATISTICAL ANALYSIS: Correlations between preoperative mpMRI and genomic characteristics of tumour and benign prostate samples were assessed. Gene profiles for individual tumour cores were correlated with existing genomic classifiers currently used for prognostication. RESULTS AND LIMITATIONS: A total of 43 prostate cores (22 tumour and 21 benign) were profiled from six whole prostate glands. Of the 22 tumour cores, 16 were tumours visible and six were tumours nonvisible on mpMRI. Intratumour genomic, epigenomic, and transcriptomic heterogeneity was found within mpMRI-visible lesions. This could potentially lead to misclassification of patients using signatures based on copy number or RNA expression. Moreover, three of the six cores obtained from mpMRI-nonvisible tumours harboured one or more genetic alterations commonly observed in metastatic castration-resistant PCa. No circulating free DNA alterations were found. Limitations include the small cohort size and lack of follow-up. CONCLUSIONS: Our study supports the continued use of systematic prostate sampling in addition to mpMRI, as avoidance of systematic biopsies in patients with negative mpMRI may mean that clinically significant tumours harbouring genetic alterations commonly seen in metastatic PCa are missed. Furthermore, there is inconsistency in individual genomics when genomic classifiers are applied. PATIENT SUMMARY: Our study shows that tumour heterogeneity within prostate tumours visible on multiparametric magnetic resonance imaging (mpMRI) can lead to misclassification of patients if only one core is used for genomic analysis. In addition, some cancers that were missed by mpMRI had genomic aberrations that are commonly seen in advanced metastatic prostate cancer. Avoiding biopsies in mpMRI-negative cases may mean that such potentially lethal cancers are missed.
引用
- Parry MA, Srivastava S, Ali A, et al. Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. Eur Urol Oncol. 2018. PMID: 30929837. doi:10.1016/j.euo.2018.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。